TESARO Inc (NASDAQ:TSRO) – Stock analysts at Piper Jaffray Companies cut their FY2021 EPS estimates for shares of TESARO in a research note issued to investors on Thursday, November 1st. Piper Jaffray Companies analyst C. Raymond now anticipates that the biopharmaceutical company will earn $0.57 per share for the year, down from their prior estimate of $0.58. Piper Jaffray Companies also issued estimates for TESARO’s FY2022 earnings at $1.68 EPS.
Several other research firms have also recently weighed in on TSRO. BidaskClub upgraded shares of TESARO from a “buy” rating to a “strong-buy” rating in a research note on Friday, October 19th. ValuEngine lowered shares of TESARO from a “hold” rating to a “sell” rating in a research report on Saturday, July 28th. Cowen reissued a “hold” rating and issued a $38.00 price target on shares of TESARO in a research report on Monday, October 22nd. Bank of America increased their price target on shares of TESARO from $38.00 to $39.00 and gave the stock a “neutral” rating in a research report on Friday. Finally, HC Wainwright dropped their price target on shares of TESARO to $71.00 and set a “buy” rating for the company in a research report on Friday, July 20th. Nine research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. TESARO currently has a consensus rating of “Buy” and a consensus price target of $78.00.
NASDAQ TSRO opened at $31.22 on Monday. The company has a debt-to-equity ratio of 3.74, a current ratio of 4.11 and a quick ratio of 3.64. TESARO has a twelve month low of $25.62 and a twelve month high of $113.75. The stock has a market capitalization of $1.66 billion, a P/E ratio of -3.40 and a beta of 1.35.
TESARO (NASDAQ:TSRO) last released its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($2.49) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.62) by $0.13. TESARO had a negative net margin of 295.67% and a negative return on equity of 563.59%. The business had revenue of $64.40 million during the quarter, compared to analysts’ expectations of $71.84 million. During the same quarter last year, the company earned ($0.47) earnings per share. The firm’s revenue was down 54.9% on a year-over-year basis.
Several hedge funds and other institutional investors have recently bought and sold shares of TSRO. US Bancorp DE increased its holdings in shares of TESARO by 163.5% during the third quarter. US Bancorp DE now owns 3,940 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 2,445 shares in the last quarter. Skylands Capital LLC acquired a new stake in shares of TESARO during the second quarter worth approximately $182,000. New Jersey Better Educational Savings Trust acquired a new stake in shares of TESARO during the third quarter worth approximately $234,000. Stifel Financial Corp acquired a new stake in shares of TESARO during the first quarter worth approximately $241,000. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of TESARO during the second quarter worth approximately $257,000.
TESARO Company Profile
Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.
Featured Story: Balance Sheet
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.